

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Link-Asia International Co. Ltd.

環亞國際實業有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

**VOLUNTARY ANNOUNCEMENT
IN RELATION TO THE EXCLUSIVE RIGHT TO SELL
AND DISTRIBUTE NOVEL CORONAVIRUS (COVID-19)
DETECTION KIT IN FIVE EUROPEAN COUNTRIES**

This announcement is made voluntarily by Link-Asia International Co. Ltd. (the “**Company**”), together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company entered into an exclusive agency agreement (the “**Exclusive Agency Agreement**”) with Shanghai BioGerm Medical Biotechnology Co., Ltd (the “**BioGerm Medical**”) on 16 March 2020, pursuant to which BioGerm Medical has granted the Company the exclusive right in five European countries including Italy, Germany, Spain, France and the United Kingdom, and non-exclusive right in other countries, to sell and distribute its Novel Coronavirus (COVID-19) detection kit related products from the date of the Exclusive Agency Agreement to 15 June 2020.

REASONS AND BENEFITS OF COOPERATION

Currently the Novel Coronavirus (COVID-19) is spreading all over the world and causing serious global challenges to the virus prevention, control and treatment. The founders of BioGerm Medical are mainly from Chinese Centre for Disease Control and Prevention (“**CCDCP**”) and Shanghai Centre for Disease Control and Prevention, with more than 15 years of experience in the field of infectious pathogens. The Novel Coronavirus (COVID-19) detection kit developed by BioGerm Medical has passed the qualifying test of CCDCP and

registered with Chinese National Medical Products Administration under Emergence Use Authorization (as of the date of this announcement, twelve similar products are approved). Up to now, BioGerm Medical has provided Novel Coronavirus diagnosis service to more than 2 million people, covering more than 80% disease control systems. It has greatly solved the problem of shortage of diagnosis for first-line medical staff, and are helping to detect patients with Novel Coronavirus accurately and quickly, identify early infection, and provide a systematic solution for epidemic prevention and control.

The Board believes that the cooperation will enable the Company to seize the business opportunity arising out of the current global fight against the epidemic and generate certain income. In addition, this move would make full use of the Company's accumulated social resources in the European and Southeast Asian countries and signify the Company's aim to contribute for the global anti-COVID-19 fight and honor its corporate responsibility.

ABOUT BIOGERM MEDICAL

BioGerm Medical is a high-tech enterprise established in the People's Republic of China, dedicated to the research, development and application of molecular diagnostic reagents for infectious pathogens, and deeply engaged in the multi fluorescence PCR diagnostic reagents. BioGerm Medical can effectively detect nearly all kinds of respiratory pathogens. More than 400 nucleic acid detection kits for pathogens manufactured by BioGerm Medical, together with its independently self-developed nucleic acid extraction reagents, have been widely used in many medical institutions across the country, undertaking nearly 60% of China's influenza sample monitoring work. At present, BioGerm Medical has applied for twenty three patents and three products has obtained the registration certificate and production license from National Medical Products Administration.

GENERAL

To the best of the directors' knowledge, information and belief having made reasonable enquiries, BioGerm Medical and its ultimate beneficial owner(s) are third parties independent of the Company and its connected person(s).

This announcement is to keep the shareholders and potential investors of the Company informed of the latest business development of the Group. Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the Shares.

By order of the Board
Link-Asia International Co. Ltd.
Lin Dailian
Chairman and executive Director

Hong Kong, 17 March 2020

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Duan Chuanhong and Mr. Xia Xiaobing as executive Directors; Mr. Bao Jinqiao, Mr. Li Huiwu and Mr. Wang Guozhen as independent non-executive Directors.